Futura Medical Share Discussion Threads

[petroc] 27/8/2022 22:05

And yet LiarBO trusted Futura's potential with CSD500 so much that he bet the farm on it! Still, I suppose he's got experience on backing the wrong horse. Now he's so bitter he can't see that MED30000 is the right horse. Poor old LiarBO! Boo hoo!

[lbo] 26/8/2022 19:55

Some shareholders remember they already failed to get Med2002/2005 extended yet again back in 2017! Yet more Futura ‘potential’ that as usual failed to materialise!!!



This patent application has the potential to extend MED2002's patent life worldwide through to 2038, thereby significantly increasing the opportunity for licensing partners to generate higher revenues and profits from the commercialisation of MED2002.

MED2002's current patent protection runs until August 2028 in the USA and August 2025 in Europe.

[lbo] 26/8/2022 19:39

A key element of Futura Medical strategy is to reduce development risk through using well characterised existing agents that are reformulated with its proprietary DermaSys technology to create new products. This means intellectual property protection is limited to use patents for the individual products and umbrella patents for the technology. There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect. The protracted development times mean the clock has been ticking on the original issued patents, reducing the protected commercial product lives.



The Emulgel technology helps the gel to penetrate deeply into the skin to enhance delivery of diclofenac to the site of pain. Voltaren Emulgel has a cooling, moisturising effect



VOLTAREN VEHICLE gel is the carrier substance of ‘Voltaren Schmerzgel’ (German trade name) or ‘Voltaren Emulgel’ (European trade name)

The cooling effect of a topically applied prod- uct can be evaluated using a validated hand- held thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results.
Consumer satisfaction with a topical product is based on subjective criteria such as how the product feels and how it is perceived on the skin. Therefore, appropriate questionnaires are of major importance for cosmetic products to assess the subjective perception not only of soothing and cooling effects but also of moistur- izing properties and fragrance.

The aim of this study was to demonstrate the sensory benefits as well as patient acceptance of the Voltaren Emulgel/Schmerzgel diclofenac- free vehicle,

[lbo] 26/8/2022 16:47

The brokers have warned about this years ago. Yet here Futura are in 2022 and the clock has run down nearly another 10 years on Dermasys!



A key element of Futura Medical’s strategy is to reduce development risk through using well characterised existing agents that are reformulated with its proprietary DermaSys technology to create new products. This means intellectual property protection is limited to use patents for the individual products and umbrella patents for the technology. There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect. The protracted development times mean the clock has been ticking on the original issued patents, reducing the protected commercial product lives.


Futura still highlights intellectual property risk as one of the Key risks for Futira




The commercial success of the Group and its ability to compete effectively with other companies depend, amongst other things, on its ability to obtain and maintain patents sufficiently broad in scope to provide protection for the Group’s intellectual property rights against
third parties and to exploit its medical products. The absence of any such patents may have a material adverse effect on the Group’s ability to develop its business.

[lbo] 26/8/2022 16:38

Dermasys when it has no drug eg GTN to deliver is not delivering anything! Med3000 is just Dermasys on its own and registered as a medical device which by definition can’t claim to be delivering any drug!

Yes Dermasys and GTN had an umbrella patent for Dermasys deliveing GTN. Just like Dermasys had with Diclofenac in TPR100.

But Dermasys on its own is off patent. The Dermasys technology is over 20 years old now. Thats how long Futura has been failing to get any commercially viable product using it!



‘The DermaSys(R) technology was originally developed by Futura for use in the
Company's topical treatment for erectile dysfunction, MED2002’

[petroc] 26/8/2022 16:35

'Our unique patented technology DermaSys® is designed to deliver clinically proven effective medical treatments via the skin.' Futura.

[lbo] 26/8/2022 16:26

To ‘assume’is based on an assumption! The assumption that the Med2005 umbrella patent of Dermasys and GTN for ED would could somehow be extended and protect Dermasys on its own for ED. Yet Dermasys on its own is over 20 years old so it has no patent anymore. And yes ‘IF’ granted it may offer some protection but very little if any ramper actually bothered to read the full patent application and actually see that the patent application is all about how the way they measured the cooling effect instead of using the handheld thermal device that GSK used! ROFLMAO




But please explain how they can get a patent that can protect Med3000. As the original Dermasys is now off patent and the evaporative cooling of any alcohol and water gel was already well described in the literature and GSK/Novartis




‘The Company has conducted initial literature and in vitro based research that has shown the cooling from the evaporation of these specific combinations of solvents’



There is a risk that some claims will either be challenged in future (eg on the grounds of non-obviousness or existence of prior art) and/or that another technology may be employed to achieve a similar effect. The protracted development times mean the clock has been ticking on the original issued patents, reducing the protected commercial products




A smooth gel intended for alcohol soluble actives. Provides cooling effect upon application while leaving minimal residue




The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results.

[petroc] 26/8/2022 16:18

"We currently assume that Futura’s patent protection on MED3000 expires in
2028 however the company has filed for additional patent protection that, if
granted, would last until 2040." Liberum.

[mikethebike4] 26/8/2022 14:57

Lbo

Are you ever going to answer any questions ? - if not why not ?

I think we all know the answer don't we

[lbo] 26/8/2022 12:04

And you too have posted ‘propaganda’ that was proven misinformation as Dermasys on its own has no patent anymore. Its just a trademark name now. Even the Dermasys trademark predates by many years the umbrella patents covering MED2005 (Dermasys and GTN) and TPR100 (Dermasys and Diclofenac) which are all expiring soon also.

from Trinity in a previous note regarding the MED2005 patent:

‘long development period resulted in a material erosion of the patent life, with the original formulation patent expected to expire in 2025’

Dermasys is even older then Med2005 so is off patent now

2002 plus 20 years = 2022



petroc - 20 Feb 2020 - 10:14:36 - 7278 of 12535

PDT, as Dermasys has been Futura's core product for several years, and upon which they base their marketing strategy, I very much doubt that it's easy to replicate faithfully or legally



GlaxoSmithKline unexpectedly handed back the development rights to Futuras erectile dysfunction gel. We are not going to progress on this particular compound for normal commercial reasons which we do not wish to go into, GSK said.



The cooling effect of a topically applied product can be evaluated using a validated handheld thermal imaging system. When the gel matrix is destroyed after application to the skin, the bound water and alcohol evaporates and a measurable cooling-effect results.





The DermaSys(R) technology was originally developed by Futura for use in the Company's topical treatment for erectile dysfunction, MED2002





Under the terms of the agreement, Thornton & Ross will conduct the manufacturing scale-up of TPR100 and hold rights to manufacture, market and distribute the product in the UK for the lifetime of the product's patents, which run to at least 2028 in the UK

[lbo] 26/8/2022 11:18

Or even J777J? He even publicly accused Lombard and the company of some sort of collusion to short the shares down to 7p so they could buy all the shares back cheaper?

J777J - 23 Dec 2019 - 08:45:36 - 7043 of 9296

Clearly feels like a stitch up by Lombard who shorted after the RNS knowing they would buy back in the placing? After all it was they that underwrote it. No TR1 announcement came from them. That after something near 35% to 40% of the company's shares changed hands!!! The mysterious Butler on their payroll????? This individual appeared out of the smoke as a duo act. The obvious tactic was to spread scare stories across the various bb's.Get the price as low as possible. Lombard appear as the white knight,the great saviours,but are they in fact ruthless market manipulators?

[lbo] 26/8/2022 11:10

Why are you not accusing Joe of ‘propaganda217;? LOL


JoeStalin - 30 Sep 2019 - 10:07:37 - 5937 of 10774
FUTURA a winner for 2015 - says it all!


JoeStalin - 18 Jul 2018 - 09:00:46 - 4354 of 10775
'jam tomorrow' is a very easy promise to make.


JoeStalin - 22 Jun 2018 - 14:12:24 - 4288 of 10775
What's another year after all?
At FUM, time is measured in decades.


JoeStalin - 25 Apr 2018 - 16:07:34 - 4147 of 10775
There seems to be an unlimited number of ways of saying "Jam tomorrow".


JoeStalin - 21 Mar 2018 - 13:50:44 - 3985 of 10775
A lifestyle company, but not for the shareholders.

[lbo] 26/8/2022 11:09

More lies from the Petroc the proven liar! Why haven't you answered why you posted a lie that it was a 'FACT' that Med3000 was 'clinically proven'. Yet unlike Futura you gave no disclaimer! Why aren't you accusing Mike of 'propaganda'?mikethebike4 - 11 Apr 2018 - 14:35:10 - 4072 of 11141Having had similar waffling, 'smoke-screen' answers from Mr Barder over the years which have turned out to end in exactly nothing I am loathe to give any credence to virtually everything he saysmikethebike4 - 11 Apr 2018 - 15:58:28 - 4091 of 11141Company is massively over valued if you go by 'concrete' results !mikethebike4 - 11 Apr 2018 - 15:14:56 - 4082 of 11141I only try and bring some sort of balance into the equation to help the gullible not get carried away with fanciful future projections.I would like nothing better than to be proved wrong about Mr Barder (our CEO since 2001) and to sale away into the sunset grasping 5 times as many £s in my fist as I paid for the sharesUnfortunately for people like J7J, Mr Barder has been through this advisors process before - with CSD500 - and look where we've got in 17 years - sales of the product did not even equal the money we paid him to be our CEO for 2017 !mikethebike4 - 06 Dec 2017 - 10:32:27 - 3468 of 10591"A couple of decent deals and will be back off to the races."Do you have any idea of how long shareholders have been using these wordsmikethebike4 - 23 Mar 2017 - 09:52:33 - 2560 of 10591As someone who has been invested for many years and who attended an AGM years ago and complained to Barder about the very slow progress, I am very frustrated.All the time the Board are drawing good salaries off the backs of shareholders money they have very little incentive to get off their backsides and get 'selling' - thats what running a company is all about at the end of the day!mikethebike4 - 24 Feb 2020 - 09:11:58 - 7290 of 9713why should it be any different this time when you've still got the same useless lot running the showmikethebike4 - 07 Jan 2019 - 11:22:52 - 4692 of 9641I repeat I very much hope you are right - no one would be happier than me if you are - however I stupidly (in hindsight) bought in when everything looked really rosy - we were told there were loads of 'distributors' all 'champing at the bit to get selling a wonderful industry disruptive product (which it still is incidentally) once the 2 year shelf-life problem was fixed. This was despite the fact that the Holland/Belgium distributor was quite happy and successful selling them with the original 18 months shelf-lifeAnd where are we now years later - one tiny distributor from which Futura receives a total sales income only just about covering Mr Barders employment remunerationI just hope this MED/TPR situation is not just a repeat of CSD. As to why I don't just sell up, well my shareholding is worth such a tiny proportion of what I paid for it I might just as well hang on in the hope that new shareholders getting in now are luckier than I was and I can get some of my money back - I think what we need is Mr Barders retirement - that should give the share price a kick

[lbo] 26/8/2022 10:33

How many shares are owned in total by the BOD? In the last annual report I think it was only 2.5m shares yet total annual renumeration was over £1m. Thats less then 1% of the total shares in issue owned by management and a equity value of less then one year’s remuneration. And how many of those shares were actually bought and how many were vested through options over the years. When was the last time the BOD bought shares and why haven’t they bought any over the last year or in the last fundraising? If they were restricted due to news flow from buying. Why they didn’t buy after the financial results? So many questions but the rampers only want to know how many shares anyone who asks legitimate questions has!? LOL

I am sure the ASA also has questions too about how a class 2 medical device gel can claim to be ‘clinically proven’ yet have no adequately controlled study to substantiate that claim?



Med3000 was the placebo in FM57. Therefore Futura had initially believed Med3000 had no therapeutic effect. The FM57 study did not set out to measure the efficacy of Med3000. The ASA will therefore consider that its reported effectiveness by Futura was a post-hoc finding



Assessment

Upheld

The ASA noted that the product appeared to meet the requirements of the Medical Device Directive (MDD) but understood that the MDD did not harmonise EU law relating the advertising of medical devices, which was subject to Directive 2005/29/EC on unfair business to consumer commercial practices (including advertising) generally (Unfair commercial practices directive - UCPD). That meant that advertisers must still meet the requirements of the CAP Code, which reflected the provisions of UCPD. Under the CAP and BCAP Codes, medical claims could be made for CE-marked medical devices provided they complied with other requirements of the Codes, including those relating to substantiation. We understood that the Aerosure Medic was classified as Class I medical device. Class I medical devices were generally CE-marked on a self-declaration basis. CE certification in itself does not constitute evidence for medical efficacy claims, and advertisers need to ensure that they hold evidence for such claims.

There was no statistically significant difference between the outcomes for the treatment group (patients using the Aerosure device) and the control group (using an inactive sham device). The study was accordingly not adequate evidence of the efficacy of the device.

[petroc] 25/8/2022 21:38

*Oh, and no, he doesn't have a holding here any more.

[haveapunt1] 25/8/2022 20:57

Lbo. Answer me this. Do you hold shares in FUM? Genuine question. Now is the rest of your position, integrity and value on this board.